![]() |
|
|
Vol. 286, Issue 1, 70-76, July 1998
Department of Pharmacology, Shinshu University School of Medicine,
Matsumoto 390-8621, Japan
There are no available data on the direct effect of C-type natriuretic
peptide (CNP) and brain natriuretic peptide (BNP) on the myocardial
contractility in mammalian hearts. Thus we studied the inotropic and
chronotropic effects of CNP-22 and BNP-32 compared with those of atrial
natriuretic peptide (ANP)-28 using the isolated, blood-perfused canine
right atrial or left ventricular preparations. CNP increased the atrial
contractile force in a dose-dependent manner with a small increase in
sinus rate in isolated atria, whereas neither ANP nor BNP changed
atrial force and rate. CNP but not BNP also increased the ventricular
contractile force in isolated ventricles. Pretreatment with a high dose
(3 nmol) of CNP attenuated the positive inotropic response to CNP at a
low dose (1 nmol) but not to norepinephrine. A guanylyl cyclase-linked natriuretic peptide receptor antagonist, HS-142-1, inhibited the increases in atrial contractile force and sinus rate in response to
CNP, but it did not affect the positive cardiac responses to norepinephrine. Propranolol did not block the positive cardiac responses to CNP. 3-Isobutyl-1-methylxanthine in rates of 0.6 to 1.3 µmol/min attenuated the CNP-induced positive inotropic responses,
when it potentiated the positive inotropic response to norepinephrine.
On the other hand, parasympathetic nerve stimulation attenuated the
positive cardiac responses to CNP and norepinephrine. These results
demonstrate that CNP increases myocardial contractile force with a
small increase in sinus rate mediated by guanylyl cyclase-linked
natriuretic peptide receptors, probably type B receptors in the dog
heart, and suggest that the positive inotropic response to CNP is
influenced by the cyclic adenosine 3',5'-monophosphate-dependent signal
transduction.
This article has been cited by other articles:
![]() |
F. Vandeput, S. L. Wolda, J. Krall, R. Hambleton, L. Uher, K. N. McCaw, P. B. Radwanski, V. Florio, and M. A. Movsesian Cyclic Nucleotide Phosphodiesterase PDE1C1 in Human Cardiac Myocytes J. Biol. Chem., November 9, 2007; 282(45): 32749 - 32757. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zaccolo and M. A. Movsesian cAMP and cGMP Signaling Cross-Talk: Role of Phosphodiesterases and Implications for Cardiac Pathophysiology Circ. Res., June 8, 2007; 100(11): 1569 - 1578. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hambleton, J. Krall, E. Tikishvili, M. Honeggar, F. Ahmad, V. C. Manganiello, and M. A. Movsesian Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3 and Their Contribution to cAMP Hydrolytic Activity in Subcellular Fractions of Human Myocardium J. Biol. Chem., November 25, 2005; 280(47): 39168 - 39174. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Su, P. M. Scholz, and H. R. Weiss Differential Effects of cGMP Produced by Soluble and Particulate Guanylyl Cyclase on Mouse Ventricular Myocytes Experimental Biology and Medicine, April 1, 2005; 230(4): 242 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Su, Q. Zhang, J. Moalem, J. Tse, P. M. Scholz, and H. R. Weiss Functional effects of C-type natriuretic peptide and nitric oxide are attenuated in hypertrophic myocytes from pressure-overloaded mouse hearts Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1367 - H1373. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Wen, X. Cui, J. Y. Jin, S. M. Kim, S. Z. Kim, S. H. Kim, H. S. Lee, and K. W. Cho High and Low Gain Switches for Regulation of cAMP Efflux Concentration: Distinct Roles for Particulate GC- and Soluble GC-cGMP-PDE3 Signaling in Rabbit Atria Circ. Res., April 16, 2004; 94(7): 936 - 943. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Rose, A. E. Lomax, and W. R. Giles Inhibition of L-type Ca2+ current by C-type natriuretic peptide in bullfrog atrial myocytes: an NPR-C-mediated effect Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2454 - H2462. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Agullo, D. Garcia-Dorado, N. Escalona, M. Ruiz-Meana, J. Inserte, and J. Soler-Soler Effect of ischemia on soluble and particulate guanylyl cyclase-mediated cGMP synthesis in cardiomyocytes Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2170 - H2176. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pierkes, S. Gambaryan, P. Boknik, S. M. Lohmann, W. Schmitz, R. Potthast, R. Holtwick, and M. Kuhn Increased effects of C-type natriuretic peptide on cardiac ventricular contractility and relaxation in guanylyl cyclase A-deficient mice Cardiovasc Res, March 1, 2002; 53(4): 852 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Herring, J. A. B. Zaman, and D. J. Paterson Natriuretic peptides like NO facilitate cardiac vagal neurotransmission and bradycardia via a cGMP pathway Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2318 - H2327. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Lee, S. Z. Kim, X. Cui, S. H. Kim, K. S. Lee, Y. J. Chung, and K. W. Cho C-type natriuretic peptide inhibits ANP secretion and atrial dynamics in perfused atria: NPR-B-cGMP signaling Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H208 - H221. [Abstract] [Full Text] [PDF] |
||||